CTOs on the Move

Hi-Tech Pharmacal Co Inc

www.multibetic.com

 
Hi-Tech Pharmacal Co Inc is a Amityville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Columbia Care

Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of medical and adult use cannabis products and related services with licenses in 18 US jurisdictions and the EU. Columbia Care is one of the original providers of medical cannabis in the United States, and continues to deliver an industry-leading, patient-centered medicinal cannabis operation that has quickly expanded into the adult use market as a premier operator. The company currently offers products spanning flower, edibles, oils, and tablets, and manufactures popular brands including Amber and Platinum Label CBD. With more than four million sales transactions since its inception in 2012, Columbia Care is known for setting the standard for compassion, professionalism, quality, care, and innovation in the rapidly expanding cannabis industry. Must be 21+ to follow.

Chartwell Pharmaceuticals

Chartwell Pharmaceuticals is a Congers, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cognosci

Cognosci is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sanofi

3129 Sanofi SA is a French multinational healthcare company headquartered in Paris, France.

Aeon Biopharma

Aeon Biopharma is leading the way as the first and only company focused solely on toxins for therapeutic applications. We are innovating toxin use to improve the lives of patients who are suffering from debilitating medical disorders. AEON is excited to introduce ABP450, the first 900 kDa toxin innovation in the US for over 30 years, and is proud to partner with physicians to advance treatment options. We are dedicated to enhancing patient lives by leading in new ways to use toxins while improving existing toxin therapy.